# A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263

> **NCT01128621** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 66 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** GSK1292263
- **DRUG:** GSK1292263 matching placebo
- **DRUG:** Sitagliptin

## Key facts

- **NCT ID:** NCT01128621
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11-23
- **Primary completion:** 2010-04-12
- **Final completion:** 2010-04-12
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2017-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01128621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01128621, "A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01128621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*